36291869 28378587 34576764 31402179 31990422 31501913 34315215 29881683 30120969 36091316 - Search Results

Year	Number of Results
2017	1
2018	2
2019	2
2020	1
2021	1
2022	3
2023	0

1

Involvement of HHV-4 (Epstein-Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis.

Marongiu L, Venturelli S, Allgayer H. Marongiu L, et al. Cancers (Basel). 2022 Oct 17;14(20):5085. doi: 10.3390/cancers14205085. Cancers (Basel). 2022. PMID: 36291869 Free PMC article.

2

Inhalable Andrographolide-β-cyclodextrin Inclusion Complexes for Treatment of Staphylococcus aureus Pneumonia by Regulating Immune Responses.

Zhang T, Zhu L, Li M, Hu Y, Zhang E, Jiang Q, Han G, Jin Y. Zhang T, et al. Mol Pharm. 2017 May 1;14(5):1718-1725. doi: 10.1021/acs.molpharmaceut.6b01162. Epub 2017 Apr 5. Mol Pharm. 2017. PMID: 28378587

3

The Impact of Human Herpesviruses in Clinical Practice of Inflammatory Bowel Disease in the Era of COVID-19.

Hosomi S, Nishida Y, Fujiwara Y. Hosomi S, et al. Microorganisms. 2021 Sep 3;9(9):1870. doi: 10.3390/microorganisms9091870. Microorganisms. 2021. PMID: 34576764 Free PMC article. Review.

4

Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term.

Rodríguez-Lago I, Merino O, López de Goicoechea MJ, Aranzamendi M, Zubiaurre L, Muro N, Ortiz de Zárate J, Cilla G, Cabriada JL. Rodríguez-Lago I, et al. Gastroenterol Hepatol. 2019 Nov;42(9):542-547. doi: 10.1016/j.gastrohep.2019.03.016. Epub 2019 Aug 8. Gastroenterol Hepatol. 2019. PMID: 31402179 English, Spanish.

5

Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Shah ED, et al. Aliment Pharmacol Ther. 2020 Mar;51(5):527-533. doi: 10.1111/apt.15637. Epub 2020 Jan 28. Aliment Pharmacol Ther. 2020. PMID: 31990422 Free PMC article.

6

[Therapeutic regimens using monoclonal antibodies in gastroenterology].

Dobsch P, Michels B, Müller-Schilling M, Kandulski A. Dobsch P, et al. Internist (Berl). 2019 Oct;60(10):1043-1058. doi: 10.1007/s00108-019-00682-2. Internist (Berl). 2019. PMID: 31501913 Review. German.

7

Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes.

Núñez Ortiz A, Rojas Feria M, de la Cruz Ramírez MD, Gómez Izquierdo L, Trigo Salado C, Herrera Justiniano JM, Leo Carnerero E. Núñez Ortiz A, et al. Rev Esp Enferm Dig. 2022 May;114(5):259-265. doi: 10.17235/reed.2021.7915/2021. Rev Esp Enferm Dig. 2022. PMID: 34315215 Free article.

8

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers.

Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. Zhang T, et al. Acta Pharm Sin B. 2018 May;8(3):440-448. doi: 10.1016/j.apsb.2018.03.004. Epub 2018 May 3. Acta Pharm Sin B. 2018. PMID: 29881683 Free PMC article.

9

Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in situ hybridization.

Pezhouh MK, Miller JA, Sharma R, Borzik D, Eze O, Waters K, Westerhoff MA, Parian AM, Lazarev MG, Voltaggio L. Pezhouh MK, et al. Hum Pathol. 2018 Dec;82:187-192. doi: 10.1016/j.humpath.2018.08.001. Epub 2018 Aug 16. Hum Pathol. 2018. PMID: 30120969

10

Epstein-Barr virus seroprevalence and viral load at disease onset in children with inflammatory bowel disease.

Kornitzer G, Rosenstein M, Turcotte MC, Godin D, Groleau V, Renaud C, Touzot F, Jantchou P, Ovetchkine P, Deslandres C. Kornitzer G, et al. JGH Open. 2022 Jul 29;6(9):625-629. doi: 10.1002/jgh3.12799. eCollection 2022 Sep. JGH Open. 2022. PMID: 36091316 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results